TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29368599

Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF) at 20 L/min, low leakage
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF) at 40 L/min, low leakage
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF) at 40 L/min, high leakage (one prong outside and open)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF) at 40 L/min, high leakage (one prong outside and closed)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF) at 40 L/min, low leakage (condition B)
Number of subjects: 36
Study: 27450228

Group type: EXPERIMENTAL
Intervention: Alectinib (exact dosage and duration not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Esomeprazole (gastric acid-reducing agent, exact dosage and duration not specified)
Number of subjects: 0
Study: 25419180

Group type: EXPERIMENTAL
Intervention: Antibiotic pretreatment
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Age above median
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Corticosteroid pretreatment
Number of subjects: 925
Study: 22133040

Group type: EXPERIMENTAL
Intervention: Evidence-based patient information
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Standard patient information
Number of subjects: 1120
Study: 19860569

Group type: EXPERIMENTAL
Intervention: Combined 10.6 microm and 650 nm laser acupuncture‐moxibustion on acupoint Dubi (ST35)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonacupoint sham control
Number of subjects: 40
Study: 17593127

Group type: EXPERIMENTAL
Intervention: Active 5Hz repetitive TMS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Active 1Hz repetitive TMS
Number of subjects: 17
Study: 15674313

Group type: EXPERIMENTAL
Intervention: 3.0 g CLA isomer blend (50:50% cis-9,trans-11:trans-10,cis-12 isomers)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Palm/bean oil blend (placebo)
Number of subjects: 60
Study: 12666951

Group type: COMPARATOR
Intervention: EDTA gel conditioning for 2 minutes (G3)
Number of subjects: 48

Group type: COMPARATOR
Intervention: EDTA gel conditioning for 2 minutes after scaling and root planing (G4)
Number of subjects: 48

Group type: COMPARATOR
Intervention: EDTA gel conditioning for 4 minutes after scaling and root planing (G5)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Scaling and root planing only (G2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: EDTA gel conditioning for 4 minutes (G5)
Number of subjects: 48
Study: 11110015

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 25
Study: 8899469

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 25
Study: 7105952

Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg tds)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31453927

Group type: EXPERIMENTAL
Intervention: Home-based couple intervention
Number of subjects: 487

Group type: COMPARATOR
Intervention: Invitation letter for clinic-based couple HIV testing
Number of subjects: 487
Study: 27894036

Group type: EXPERIMENTAL
Intervention: Intensive and brief psychodynamic psychotherapy (IBPP)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 149
Study: 25602290

Group type: EXPERIMENTAL
Intervention: TAU plus manualized CBT informed Victim Improvement Package (VIP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 26
Study: 24737459

Group type: EXPERIMENTAL
Intervention: Anemia at discharge
Number of subjects: 3731

Group type: COMPARATOR
Intervention: Baseline anemia
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Discharge anemia
Number of subjects: 3731

Group type: COMPARATOR
Intervention: No anemia at baseline
Number of subjects: 3731
Study: 22250828

Group type: EXPERIMENTAL
Intervention: Loozit® weight management programme with additional therapeutic contact via telephone coaching and electronic communications
Number of subjects: 12

Group type: COMPARATOR
Intervention: Loozit® weight management programme
Number of subjects: 12
Study: 19254366

Group type: EXPERIMENTAL
Intervention: 150 mg of IGOB131
Number of subjects: 102

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 102
Study: 17451414

Group type: EXPERIMENTAL
Intervention: Behçet's disease patients (BD)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Recurrent aphthous stomatitis patients (RAS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 86
Study: 10749962

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal renal angioplasty
Number of subjects: 106

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 106
Study: 8874746

Group type: EXPERIMENTAL
Intervention: Topical melatonin 0.5%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical melatonin 0.05%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carrier alone
Number of subjects: 20
Study: 1573135

Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention
Number of subjects: 894

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 894
Study: 4014216

Group type: EXPERIMENTAL
Intervention: Computer-assisted telephone interviewing
Number of subjects: 400

Group type: COMPARATOR
Intervention: Hard copy telephone interviewing
Number of subjects: 400
Study: 30761783

Group type: EXPERIMENTAL
Intervention: Fosfomycin + Phytolysin (3g fosfomycin single dose, Phytolysin three times daily for a month)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Fosfomycin (3g single dose)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fosfomycin + Phytolysin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Fosfomycin
Number of subjects: 63
Study: 26549151

Group type: EXPERIMENTAL
Intervention: Reward
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Punishment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study: 24762149

Group type: EXPERIMENTAL
Intervention: Allogeneic cancellous bone sponge
Number of subjects: 25
Study: 22955035

Group type: EXPERIMENTAL
Intervention: UMEC/VI (500/25 mcg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 20980494

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet (LoGIX; 40 ± 0.3 units)
Number of subjects: 22

Group type: COMPARATOR
Intervention: High-glycemic index diet (HiGIX; 80 ± 0.6 units)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Exercise training (1 h/d for 5 d/wk at ≈ 85% of maximum heart rate)
Number of subjects: 22
Study: 18622640

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (180-540 mg daily for 6 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neostigmine (acute effects assessed)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (2 weeks)
Number of subjects: 10
Study: 15842865

Group type: EXPERIMENTAL
Intervention: Radiation group (30 patients)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (28 patients)
Number of subjects: 58
Study: 12699092

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.15 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg
Number of subjects: 100
Study: 10598611

Group type: EXPERIMENTAL
Intervention: Epidural lidocaine (300 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Epidural saline control
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Epidural saline-intravenous lidocaine infusion
Number of subjects: 44
Study: 8524760

Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy and a course of microwave therapy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 136
Study: 1957647

Group type: EXPERIMENTAL
Intervention: Myoblast injection (approximately 8 x 10(6) myoblasts)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham injection (carrier solution)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Myoblast injection with Cyclosporine (CsA) treatment (started two days before injection and continued for three months)
Number of subjects: 3
Study: 31419219

Group type: EXPERIMENTAL
Intervention: Occupational intervention (n = 153)
Number of subjects: 305

Group type: COMPARATOR
Intervention: No additional intervention (control group; n = 152)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Intervention arm with workplace visit (n = 40)
Number of subjects: 305
Study: 28153946

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 35
Study: 26819953

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo Taping (PT)
Number of subjects: 17
Study: 23381945

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in patients with moderate Wwox expression
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in patients with strong Wwox expression
Number of subjects: 912

Group type: COMPARATOR
Intervention: Untreated patients with absent Wwox expression
Number of subjects: 912
Study: 21277076

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TVT-Secur
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mini-Arc
Number of subjects: 90
Study: 21181319

Group type: EXPERIMENTAL
Intervention: Esomeprazole (80 mg/30 minutes, then 8 mg/hour for 71.5 hours)
Number of subjects: 764

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 764
Study: 16504281

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 17% carbamide peroxide
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0% carbamide peroxide (control)
Number of subjects: 30
Study: 15585551

Group type: EXPERIMENTAL
Intervention: Partial substitution of 50 microg T4 by 10 microg T3
Number of subjects: 697

Group type: COMPARATOR
Intervention: Original dose of T4 (control group)
Number of subjects: 697
Study: 12038448

Group type: EXPERIMENTAL
Intervention: Three-step high-dose chemotherapy (HDT) with autologous peripheral blood progenitor cell (PBPC) transplant
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Three-step high-dose chemotherapy (HDT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Monitoring of molecular disease in CR patients by PCR
Number of subjects: 20
Study: 10633637

Group type: EXPERIMENTAL
Intervention: Constipation risk assessment scale and bowel management protocol
Number of subjects: 0
Study: 7786834

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 35
Study: 2132893

Group type: EXPERIMENTAL
Intervention: Verbal model (visual demonstration with verbal cues)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No model (verbal instructions only)
Number of subjects: 80
Study: 7468558

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Metoclopramide vs Placebo
Number of subjects: 55
Study: 31397703

Group type: EXPERIMENTAL
Intervention: Small-fragment plating (single 3.5-mm locking compression plate)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Mini-fragment plating (orthogonal plating with 2.7-mm reconstruction plates)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Mini-fragment plating
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study: 28270329

Group type: EXPERIMENTAL
Intervention: Imaginal homework adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate imaginal homework adherence (two or more times a week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher ratings of helpfulness of both types of homework
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo homework adherence
Number of subjects: 0
Study: 26172895

Group type: EXPERIMENTAL
Intervention: Patiromer 4.2 g twice daily
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Patiromer 8.4 g twice daily
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Patiromer 12.6 g twice daily
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Patiromer 8.4 g twice daily (moderate hyperkalemia)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Patiromer 12.6 g twice daily (moderate hyperkalemia)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Patiromer 16.8 g twice daily (moderate hyperkalemia)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Patiromer (all doses)
Number of subjects: 306
Study: 23325525

Group type: EXPERIMENTAL
Intervention: Watchman device
Number of subjects: 707

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 707
Study: 21299902

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 19889888

Group type: EXPERIMENTAL
Intervention: Automated SAE summary
Number of subjects: 806
Study: 16441622

Group type: EXPERIMENTAL
Intervention: BMV 0.1% tape
Number of subjects: 42

Group type: COMPARATOR
Intervention: BMV 0.12% cream
Number of subjects: 42
Study: 15313287

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.4% ophthalmic solution (Acular(R) LS), n = 156, 4 times daily for up to 4 days
Number of subjects: 313

Group type: COMPARATOR
Intervention: Vehicle (control), n = 157, 4 times daily for up to 4 days
Number of subjects: 313
Study: 11744142

Group type: COMPARATOR
Intervention: Diabetic patients
Number of subjects: 88
Study: 9468005

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (LS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-potassium diet (HK)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-calcium diet (HCa)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined low-sodium, high-potassium, high-calcium diet (LS, HK, HCa)
Number of subjects: 36
Study: 8512397

Group type: EXPERIMENTAL
Intervention: Thoracic epidural fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lumbar epidural fentanyl
Number of subjects: 30
Study: 2455111

Group type: EXPERIMENTAL
Intervention: Felodipine treatment
Number of subjects: 10
Study: 29689482

Group type: EXPERIMENTAL
Intervention: Adventure-based training programme (4-day duration)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 222
Study: 27406346

Group type: EXPERIMENTAL
Intervention: Neratinib added to standard neoadjuvant chemotherapy
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard chemotherapy with trastuzumab (Control)
Number of subjects: 193
Study: 24927078

Group type: EXPERIMENTAL
Intervention: GnRH-antagonist protocol
Number of subjects: 80

Group type: COMPARATOR
Intervention: long‐GnRH‐agonist protocol
Number of subjects: 80
Study: 21880023

Group type: EXPERIMENTAL
Intervention: 12 week exercise program including aerobic and strengthening exercises, conducted between week 20 and 36 of pregnancy, with one weekly group session led by physiotherapists and home exercises encouraged twice a week.
Number of subjects: 855

Group type: COMPARATOR
Intervention: Regular antenatal care (Control)
Number of subjects: 855
Study: 20557387

Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-massage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Professional massage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (laxatives)
Number of subjects: 60
Study: 18407413

Group type: EXPERIMENTAL
Intervention: Leech therapy (2-3 locally applied leeches)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Topical diclofenac (30-day course, twice a day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Leech therapy
Number of subjects: 32
Study: 16598181

Group type: EXPERIMENTAL
Intervention: Scene 2 (environment where the patient feels strong anxiety)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Scene 1 (environment where the patient feels safe and comfortable)
Number of subjects: 57
Study: 11874430

Group type: EXPERIMENTAL
Intervention: Glibenclamide (15 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glimepiride (6 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metformin (1500 mg/day)
Number of subjects: 24
Study: 10195783

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine alone
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine with immune globulin (Ig) concurrently
Number of subjects: 301

Group type: COMPARATOR
Intervention: Ig alone
Number of subjects: 301
Study: 7851164

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Medical and surgical treatment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Surgical treatment (anal surgeries including abscess drainage and fistulotomy)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Intestinal surgery for rectovaginal fistulas
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Recurrence of anal disease requiring further surgery
Number of subjects: 225
Study: 2341995

Group type: EXPERIMENTAL
Intervention: Initial emotional upset
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Delayed emotional reaction
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Low average levels of emotional upset
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: High level of initial emotional upset that subsided
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Increasing levels of emotional distress long-term follow-up
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Failure to achieve long-term emotional readjustment
Number of subjects: 283
Study: 387010

Group type: EXPERIMENTAL
Intervention: Flunisolide intranasal spray
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 31687867

Group type: EXPERIMENTAL
Intervention: Virtual reality-delivered mirror visual feedback (VR-MVF) and exposure therapy (VR-ET)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-embodied virtual reality sessions (control)
Number of subjects: 14
Study: 28556616

Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 43
Study: 26848148

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg LD/10 mg MD q.d.)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg LD/90 mg MD b.i.d)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Clopidogrel (previous treatment)
Number of subjects: 110
Study: 25452426

Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 125/25 mcg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22238169

Group type: EXPERIMENTAL
Intervention: Azithromycin PEP
Number of subjects: 86

Group type: COMPARATOR
Intervention: No PEP (daily symptom monitoring)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Comparison of Azithromycin PEP vs No PEP
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 86
Study: 20028938

Group type: EXPERIMENTAL
Intervention: 20% intralipid infusion at 40 ml/h for 48 h
Number of subjects: 25
Study: 18158504

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2166

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 2166
Study: 16010209

Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous stem cell transplantation (HDT-ASCT)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 575
Study: 12711469

Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Psoralen-ultraviolet A (PUVA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Coal tar
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Number of subjects: 56
Study: 10663427

Group type: EXPERIMENTAL
Intervention: 0.50 g/kg of 10% (v/v) alcohol solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.75 g/kg of 10% (v/v) alcohol solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.00 g/kg of 10% (v/v) alcohol solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.25 g/kg of 10% (v/v) alcohol solution
Number of subjects: 10
Study: 8680488

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1298086

Group type: EXPERIMENTAL
Intervention: 480 mg total dose of artemether given over 5 days
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: 600 mg total dose of artemether given over 5 days
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Both dosage regimens (480 mg and 600 mg)
Number of subjects: 167
Study: 6094446

Group type: EXPERIMENTAL
Intervention: 1 g of intravenous injection of cefotaxime at the time of induction of anaesthesia
Number of subjects: 66

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 66
Study: 30043658

Group type: EXPERIMENTAL
Intervention: ozanimod hydrochloride 0.5 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: ozanimod hydrochloride 1 mg
Number of subjects: 249

Group type: COMPARATOR
Intervention: placebo → ozanimod hydrochloride 0.5 mg
Number of subjects: 249

Group type: COMPARATOR
Intervention: placebo → ozanimod hydrochloride 1 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: ozanimod treatment
Number of subjects: 249
Study: 30272388

Group type: EXPERIMENTAL
Intervention: Unattended SPRINT BP measurements (139.77 ± 19.22/75.42 ± 11.72 mm Hg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Unattended SPRINT BP measurements
Number of subjects: 65

Group type: COMPARATOR
Intervention: Unobserved SPRINT-like BP measurements
Number of subjects: 65